Ujjani, C., Wang, H., Skarbnik, A., Trivedi, N., Ramzi, P., Khan, N., & Cheson, B. D. (2018). A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. Blood Adv.
शिकागो स्टाइल उद्धरणUjjani, Chaitra, Hongkun Wang, Alan Skarbnik, Neel Trivedi, Pari Ramzi, Nadia Khan, और Bruce D. Cheson. "A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL." Blood Adv 2018.
एमएलए उद्धरणUjjani, Chaitra, et al. "A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL." Blood Adv 2018.
चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.